Welcome to our dedicated page for Vicore Pharma Holding AB SEC filings (Ticker: VCRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Vicore Pharma Holding AB's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Vicore Pharma Holding AB's regulatory disclosures and financial reporting.
Vicore Pharma Holding AB (VCRE) reported second-quarter 2026 results as a clinical-stage company advancing its ATRAG pipeline, led by buloxibutid for idiopathic pulmonary fibrosis. Enrollment in the global 52-week Phase 2b ASPIRE trial was completed with more than 360 patients randomized, with topline data expected in mid-2027. After the quarter, Vicore’s American Depositary Shares began trading on the Nasdaq Capital Market under ticker VCRE, complementing its Nasdaq Stockholm listing.
Net revenues for April–June 2026 were SEK 2.2 million (USD 0.2 million). The company reported an operating loss of SEK 150.1 million (USD 16.0 million) and a loss for the period of SEK 142.8 million (USD 15.3 million), with loss per share of SEK 0.51 (USD 0.05). Research and development expenses represented 78.0% of operating expenses, underscoring the R&D focus.
Equity at June 30, 2026 was SEK 853.6 million (USD 87.7 million). Cash, cash equivalents, and short-term investments totaled SEK 905.6 million (USD 93.0 million), with cash flows used in operating activities of SEK 155.9 million (USD 16.7 million) in the quarter. Management states this supports a cash runway extending into the second half of 2028, providing visibility through the ASPIRE readout.
Vicore Pharma Holding has appointed Rob Slack, PhD, FRSB as Chief Scientific Officer, succeeding Johan Raud, MD, PhD, who will transition to Senior Advisor. Dr. Slack brings over 20 years of leadership in fibrosis and respiratory translational science, including senior roles at GSK as Vice President and Head of Respiratory Biology and prior service as acting Chief Scientific Officer at Galecto. He has contributed to multiple approved respiratory medicines for asthma, COPD and IPF and has more than 60 scientific publications. As Chief Scientific Officer, he will lead Vicore’s research strategy and development of its next-generation angiotensin II type 2 receptor agonist pipeline, including the lead program buloxibutid, which is in a global 52‑week Phase 2b ASPIRE trial in idiopathic pulmonary fibrosis and holds Orphan Drug and Fast Track designations from the U.S. FDA.